glp 1 and gip agonist Frontiers The dual glucose-dependent insulinotropic polypeptide

"Retatrutide Clinical Development: Safety and Efficacy in Phase 2 Trials." Clinical Endocrinology and Metabolism Review, 2024

Japan grows at 6.4%, benefiting from advancements in diabetes management and increasing patient access to innovative therapies

This can significantly increase fall risk , especially in older adults already dealing with sarcopenia

Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 29(3), 219224

The reduction of visceral fat is regarded as one of the non-glucose-lowering effects of GLP-1RAs, such as liraglutide [54], which may contribute to myocardial protection